HSBC analyst Yifeng Liu upgraded Moderna to Hold from Reduce with a price target of $69, down from $89. The firm says Moderna’s 2024 guidance of a minimum of $4B revenue was below its bearish expectation. However, the analyst believes the current share price adequately reflects the current outlook for Moderna. HSBC says the downside has played out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA: